Eventos adversos a fármacos modificadores de la enfermedad en pacientes con artritis reumatoide de inicio

Abstract

The prognosis of Rheumatoid Arthritis (RA) has improved dramatically inrecent years, especially with the use of disease-modifying drugs (DMARDs), but this progress is overshadowed by the risk of developing adverse events (AE) to these drugs. After more than twenty years using them, their effectiveness is widely known, but it is necessary to increase our knowledge about their AE, especially those that require drug discontinuation and especially outside of clinical trial conditions. The purpose of this study was to analyze the discontinuation of the different DMARDs due to the development of moderate or serious adverse events in patients with recent onset RA indaily clinical practice...